CD8A and coinfection: We evaluated biomarkers such as age, gender, CD4 cell count and CD4:CD8 ratio at the beginning of the therapy, HIV viral load at the beginning of ART, the existence of acute HIV infection, HCV or HBV coinfections, comorbidities or opportunistic infections.